Palatin partners with UpScriptHealth to expand Vyleesi access via telehealth platform

PALATIN TECHNOLOGIES INC

Palatin (PTN) entered strategic partnership with telemedicine company UpScriptHealth.
Vyleesi, the first FDA-approved as-needed HSDD treatment, will be on UpScriptHealth's Women's Telehealth Platform.
UpScriptHealth's patient base is hundreds of thousands of women; partnership aims to boost HSDD awareness.
Palatin CEO Carl Spana said the deal fortifies existing telehealth programs and expands patient access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.